Business Context and Reporting Period
This Form 8-K is filed by Entero Therapeutics, Inc. (not Gridai Technologies Corp.) on August 21, 2024. The report addresses a regulatory compliance issue regarding the company's listing status on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding a listing notice and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Delisting Notice: The company received a notice from Nasdaq on August 21, 2024, stating it is not in compliance with Listing Rule 5250(c)(1) due to the failure to timely file its Form 10-Q for the period ended June 30, 2024.
- Cause of Delay: The delay in filing the 10-Q is attributed to the company's process of engaging a new independent registered public accounting firm.
- Compliance Timeline: The company has 60 days (until October 21, 2024) to submit a compliance plan. If approved, Nasdaq may grant an extension of up to 180 days (until February 17, 2025).
Outlook, Risks, and Management Commentary
- Immediate Impact: The notice has no immediate effect on the listing or trading of the company's common stock.
- Management Action: Management intends to take necessary steps to regain compliance as soon as practicable while finalizing the engagement of a new auditor.
- Risk: Failure to regain compliance within the allotted timeframe could result in delisting from the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the status of the new independent registered public accounting firm engagement.
- Monitor the submission of the compliance plan to Nasdaq by the October 21, 2024 deadline.
- Review the upcoming Form 10-Q for the period ended June 30, 2024, once filed, to assess actual financial performance.
- Confirm that trading of the common stock (Symbol: ENTO) remains unaffected during the compliance period.